Dexcom Stock News

DexCom press release (DXCM): Q4 Non-GAAP EPS of $0.68 misses by $0.17.Revenue of $698.2M (+22.7% Y/Y) in-line.U.S. revenue growth of 15% and international revenue growth of 54% on…

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Dexcom, Inc. (DXCM) CEO Kevin Sayer on Q4 2021 Results - Earnings Call Transcript

DexCom (DXCM) delivered earnings and revenue surprises of -20.93% and 0.03%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

If history is any guide, there may be trouble ahead for shares … Full story available on Benzinga.com

DexCom (NASDAQ:DXCM) is scheduled to announce Q4 earnings results on Thursday, February 10th, after market close.The consensus EPS Estimate is $0.85 (-6.6% Y/Y) and the consensus…

Tech stocks got off to a positive start Wednesday morning. The Nasdaq traded up about 1.3%, the S&P 500 was up 1.04% and the Dow traded 0.7% higher shortly after the opening bell.

Both companies still have miles of growth left ahead.

Dexcom (DXCM) said people with diabetes who are under 18 years of age and require ongoing use of insulin or insulin pump therapy are eligible for public coverage of Dexcom G6 CGM…

Analysts have provided the following ratings for DexCom (NASDAQ: DXCM ) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 2 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 2 1 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 These 5 analysts have an average price target of $559.6 versus the current price of DexCom at $424.72, implying upside. Below is a summary of how these 5 analysts rated DexCom over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater … Full story available on Benzinga.com

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

DexCom One and G7 can prove to be a solid growth catalysts for this leading CGM player. DexCom has also secured FDA approval for two key software solutions, which can further help the company integrat

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time